Summary

Japan Onychomycosis Market Research Report: Size, Share, Trend Analysis By Types (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candida Onychomycosis, Others), By Treatment Type (Drug Treatment, Topical Therapy, Others) and By End Users (Hospital Pharmacies, Retail Pharmacies, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Market Summary:
As per Market Research Future analysis, the Japan onychomycosis market Size was estimated at 156.38 USD Million in 2024. The Japan onychomycosis market is projected to grow from 162.69 USD Million in 2025 to 241.73 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 4.0% during the forecast period 2025 - 2035

Market Drivers:
The growing demand for topical treatments is a notable driver of the onychomycosis market in Japan. Patients often prefer non-invasive treatment options that can be applied directly to the affected area, minimizing systemic side effects. Recent market analysis indicates that topical antifungal agents account for a substantial share of the overall market, with a projected growth rate of around 8-10% annually. This trend is likely fueled by the increasing availability of over-the-counter topical solutions, which empower patients to manage their condition independently. As awareness of these options expands, the onychomycosis market is expected to experience a corresponding increase in sales of topical treatments, reflecting a shift in patient preferences towards more accessible and user-friendly solutions. The rising incidence of onychomycosis in Japan is a critical driver for the onychomycosis market. Recent studies indicate that approximately 10-15% of the population may be affected by this fungal infection, particularly among older adults.

Market Segment Analysis:
The Japan Onychomycosis Market, under the Type segment, encompasses a broad range of conditions affecting toenails and fingernails, with each type presenting unique characteristics and treatment challenges. Distal Subungual Onychomycosis is the most prevalent form, caused primarily by dermatophytes, and it typically leads to thickened, discolored nails, often prompting individuals to seek treatment due to aesthetic concerns and discomfort. This condition is particularly significant in Japan, where traditional notions of beauty often emphasize well-groomed nails, creating a strong demand for effective treatment options. White Superficial Onychomycosis, although less common than its distal counterpart, affects the superficial layers of the nail and presents a challenge as it can be misidentified as a cosmetic issue rather than a fungal infection. Awareness and proper diagnosis of this condition are vital since it often leads to effective management strategies when recognized early.

Regional Analysis:
The onychomycosis market in Japan is currently experiencing notable developments, driven by a combination of increasing awareness regarding fungal infections and advancements in treatment options. The prevalence of onychomycosis, characterized by fungal nail infections, has prompted healthcare professionals to seek effective solutions. As a result, there is a growing demand for antifungal medications, topical treatments, and innovative therapies. Furthermore, the aging population in Japan appears to contribute to the rising incidence of this condition, as older individuals are more susceptible to nail infections. This demographic shift may lead to an expanded market for onychomycosis treatments, as healthcare providers focus on addressing the needs of this population.

Major Players:
The following companies are key participants in the Japan Onychomycosis Market, playing a crucial role in market development through technological innovation, strategic partnerships, and competitive product offerings.

ページTOPに戻る

Table of Contents

TABLE OF CONTENT
1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
EXECUTIVE SUMMARY
Market Overview
Key Findings
Market Segmentation
Competitive Landscape
Challenges and Opportunities
Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
MARKET INTRODUCTION
Definition
Scope of the study
Research Objective
Assumption
Limitations
RESEARCH METHODOLOGY
Overview
Data Mining
Secondary Research
Primary Research
Primary Interviews and Information Gathering Process
Breakdown of Primary Respondents
Forecasting Model
Market Size Estimation
Bottom-Up Approach
Top-Down Approach
Data Triangulation
Validation
3 SECTION III: QUALITATIVE ANALYSIS
MARKET DYNAMICS
Overview
Drivers
Restraints
Opportunities
MARKET FACTOR ANALYSIS
Value chain Analysis
Porter's Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of New Entrants
Threat of Substitutes
Intensity of Rivalry
COVID-19 Impact Analysis
Market Impact Analysis
Regional Impact
Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
Japan Onychomycosis Market Segmentation
Onychomycosis Type Outlook (USD Billion, 2019-2030)
Distal Subungual Onychomycosis (DSO)
White Superficial Onychomycosis (WSO)
Proximal Subungual Onychomycosis (PSO)
Candida Onychomycosis
Others
Onychomycosis Treatment Type Outlook (USD Billion, 2019-2030)
Drug Treatment
Topical Therapy
Others
Japan Onychomycosis End User Outlook (USD Billion, 2019-2030)
Hospital Pharmacies
Retail Pharmacies
Others
Onychomycosis SECTION V: COMPETITIVE ANALYSIS
Competitive Landscape
Overview
Competitive Analysis
Market share Analysis
Major Growth Strategy in the onychomycosis market
Competitive Benchmarking
Leading Players in Terms of Number of Developments in the onychomycosis market
Key developments and growth strategies
New Product Launch/Service Deployment
Merger & Acquisitions
Joint Ventures
Major Players Financial Matrix
Sales and Operating Income
Major Players R&D Expenditure. 2023
Company Profiles
Eisai Co
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Takeda Pharmaceutical Company Limited
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Mitsubishi Tanabe Pharma Corporation
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Daiichi Sanky
Company Limited
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Astellas Pharma Inc
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Kaken Pharmaceutical C
Ltd
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Santen Pharmaceutical C
Ltd
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Otsuka Pharmaceutical C
Ltd
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Appendix
References
Related Reports

COMPANIES MENTIONED
Eisai Co, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Astellas Pharma Inc, Kaken Pharmaceutical Co Ltd, Santen Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd

ページTOPに戻る

List of Tables/Graphs

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 JAPAN ONYCHOMYCOSIS MARKET ANALYSIS BY TYPE
FIGURE 3 JAPAN ONYCHOMYCOSIS MARKET ANALYSIS BY TREATMENT TYPE
FIGURE 4 JAPAN ONYCHOMYCOSIS MARKET ANALYSIS BY END USER
FIGURE 5 KEY BUYING CRITERIA OF ONYCHOMYCOSIS MARKET
FIGURE 6 RESEARCH PROCESS OF MRFR
FIGURE 7 DRO ANALYSIS OF JAPAN ONYCHOMYCOSIS MARKET
FIGURE 8 DRIVERS IMPACT ANALYSIS: JAPAN ONYCHOMYCOSIS MARKET
FIGURE 9 RESTRAINTS IMPACT ANALYSIS: JAPAN ONYCHOMYCOSIS MARKET
FIGURE 10 SUPPLY / VALUE CHAIN: JAPAN ONYCHOMYCOSIS MARKET
FIGURE 11 JAPAN ONYCHOMYCOSIS MARKET, BY TYPE, 2024 (% SHARE)
FIGURE 12 JAPAN ONYCHOMYCOSIS MARKET, BY TYPE, 2024 TO 2035 (USD Million)
FIGURE 13 JAPAN ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2024 (% SHARE)
FIGURE 14 JAPAN ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
FIGURE 15 JAPAN ONYCHOMYCOSIS MARKET, BY END USER, 2024 (% SHARE)
FIGURE 16 JAPAN ONYCHOMYCOSIS MARKET, BY END USER, 2024 TO 2035 (USD Million)
FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS

LIST OF TABLES
LIST OF ASSUMPTIONS
Japan ONYCHOMYCOSIS MARKET SIZE ESTIMATES; FORECAST
TABLE 1 BY TYPE, 2026-2035 (USD Million)
TABLE 2 BY TYPE, 2026-2035 (USD Million)
TABLE 3 BY TREATMENT TYPE, 2026-2035 (USD Million)
TABLE 4 BY TREATMENT TYPE, 2026-2035 (USD Million)
TABLE 5 BY END USER, 2026-2035 (USD Million)
TABLE 6 BY END USER, 2026-2035 (USD Million)
PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
ACQUISITION/PARTNERSHIP